Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922452 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
A Phase 1 study of Ischemic Stroke, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02922452: Completed Phase 1 study of Ischemic Stroke, sponsored by Bristol-Myers Squibb.
NCT02922452 is a Phase 1 study of Ischemic Stroke that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02922452, a Phase 1 study of Ischemic Stroke, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with parameters like Cmax, AUC(INF), and AUC(0-T).
Conditions Studied
Interventions
- DRUG BMS-986141
- DRUG Dilitazem
Study Locations (1)
Texas
- PPD Development - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-09 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
What the finished NCT02922452 record still lists
NCT02922452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which BMS-986141 is the first listed.
NCT02922452 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02922452 about?
NCT02922452 is a clinical study titled "A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects". This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with parameters like Cmax, AUC(INF), and AUC(0-T).
What is the current status of trial NCT02922452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-09. Estimated completion is 2016-11.
What conditions does trial NCT02922452 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT02922452?
The interventions under investigation include: BMS-986141 (DRUG), Dilitazem (DRUG).
Who is sponsoring clinical trial NCT02922452?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02922452 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02922452's enrollment target sits among peer trials
16 61st of 66 higher than 5 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Verapamil for Neuroprotection in Stroke
RECRUITING · Phase 1
-
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of NCS-01 in Patients With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 1
-
Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living
COMPLETED · Phase 1
-
The Capillary Index Score Trial
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia